Find Academic Supervisors

Prof. Waldemar Kolanus leads the Molecular Immunology and Cell Biology department at the University of Bonn's Life & Medical Sciences Institute (LIMES) . His research bridges immunoregulation , stem cell dynamics , and metabolic stress responses in immune cells. Unit 2 member at LIMES Principal investigator in SFB 704 and ImmunoSensation Cluster Leads a multidisciplinary lab with postdocs, PhD students, and technical staff His work focuses on intracellular signaling pathways connecting immune activation to tissue homeostasis, particularly through: Cytohesin proteins in integrin-mediated adhesion and migration TRIM71 in stem cell regulation and congenital hydrocephalus High-salt environments affecting macrophage function Publication trends show expertise in immune cell migration , genetic models , and chemical inhibition , with frequent use of mice and zebrafish for in vivo studies. Key articles explore: TRIM71's dual role in auditory development and germ cell maintenance Cytohesin family's Golgi regulation and insulin signaling Ruxolitinib's off-target migration inhibition of dendritic cells Contact details: Address: LIMES Institute, Carl-Troll-Straße 31, Bonn Email: kolanus.sekretariat@uni-bonn.de Phone: +49 228 73-62788

• Molecular Immunology
• Cell Signaling
• Signal Transduction Pathways
• +4 more

Tobias Dick serves as Professor and Head of the Division of Redox Regulation at the German Cancer Research Center (DKFZ) in Heidelberg, maintaining a primary affiliation with Heidelberg University's Faculty of Biosciences. His leadership spans molecular switch research within the SFB/TRR186 consortium focusing on spatio-temporal control of cellular signal transmission. Academic Background: PhD in Biochemistry, Freie Universität Berlin (1997, summa cum laude) Habilitation in Biochemistry, Heidelberg University (2009) Diploma thesis at German Cancer Research Center (1994) Study program in Biochemistry, Freie Universität Berlin (1989-1994) Research Focus: Dick pioneers investigations into thiol-based redox switches governing cellular signal transduction. His work establishes fundamental mechanisms of peroxiredoxin-mediated hydrogen peroxide signaling, protein persulfidation dynamics, and sulfur-based radical scavenging systems. Key contributions include developing real-time imaging probes for redox species and elucidating redox relays connecting peroxiredoxins to transcription factors like STAT3. Current research explores hydropersulfide protection against ferroptosis and metabolic adaptation through redox-sensitive enzymes. Publication Trends: Over 15 years of high-impact publications reveal an evolutionary trajectory from foundational redox imaging techniques (2008-2011) to sophisticated molecular mechanism studies (2013-2020), culminating in recent breakthroughs on sulfur signaling in cell death pathways (2023). His work consistently appears in premier journals like Nature Chemical Biology , demonstrating sustained innovation in redox biology methodology and conceptual frameworks. Scientific Recognition: ERC Advanced Grant (2017) Society for Free Radical Research Europe Basic Science Award (2017) Chica- and Heinz-Schaller-Award for young scientists (2009) Marie Curie Excellence Grant (2004) DFG Postdoctoral Fellowship (1998-2000) Studienstiftung des Deutschen Volkes Scholarship (1989-1994) Leadership & Mentorship: As founding vice-coordinator of DFG priority program SPP1710 (2014-present) and GBM Redox Biology Study Group (2011-2017), Dick shapes national research agendas. His division at DKFZ mentors next-generation scientists through ERC and DFG-funded projects, with trainees contributing to landmark publications on redox switches and cellular physiology. Research Infrastructure: The Division of Redox Regulation operates within DKFZ's state-of-the-art facilities, collaborating extensively through the SFB/TRR186 consortium. This environment enables cutting-edge investigations into redox-controlled cellular processes using advanced biochemical, imaging, and computational approaches.

• Redox Biology
• Signal Transduction
• Cellular Physiology
• +3 more

Dr. Andrew Bassett serves as Head of the Cellular and Gene Editing Research group at the Wellcome Sanger Institute, where he develops cutting-edge genome engineering techniques using human pluripotent stem cells to investigate neurodegenerative diseases including Alzheimer's and Parkinson's. His work focuses on scaling genetic screening approaches and improving CRISPR specificity for modeling complex disease mechanisms. His academic training includes: PhD at the MRC Laboratory of Molecular Biology (MRC-LMB) with Andrew Travers on chromatin remodelling in heterochromatin formation Postdoctoral research with David Baulcombe at the University of Cambridge studying small RNA roles in chromatin modification Additional postdoctoral work with Chris Ponting at the MRC Functional Genomics Unit (MRC-FGU) in Oxford, where he pioneered CRISPR applications in Drosophila Bassett's research program centers on developing advanced genome engineering methodologies for precise modulation of gene expression networks during development and neurodegeneration. His group specializes in creating complex editing events (SNPs, paired knockouts, enhancer perturbations) within iPSC-derived models, with particular emphasis on epigenetic regulation and transcriptional control. Current projects integrate single-cell 'omics and phenotypic assays to decode genetic causes of neurodegenerative disorders through the OpenTargets consortium. Analysis of his 15 most recent publications reveals dominant trends in CRISPR technology development (35%), neurodegenerative disease modeling (30%), and single-cell functional genomics (25%). His work consistently bridges methodological innovation with disease mechanism studies, increasingly incorporating multi-omics approaches and expanding into cancer immunology and infectious disease applications since 2022. As group leader, Bassett mentors postdoctoral researchers and PhD students while securing major funding for genome engineering initiatives. His team operates within the Sanger Institute's Cellular Operations division and maintains critical partnerships with the OpenTargets consortium for therapeutic target validation. The laboratory specializes in high-throughput screening platforms using iPSC-derived neural and microglial models, with recent methodological advances including scSNV-seq and ONE-STEP tagging systems that significantly enhance precision genome editing capabilities.

• Genome Engineering
• Neurodegenerative Diseases
• Stem Cell Research
• +5 more

Brenda Schulman is a Professor and Director of the Molecular Machines and Signaling Pathways department at the Max Planck Institute of Biochemistry in Martinsried, Germany. She also holds an honorary professorship at the Technical University of Munich's Department of Chemistry and serves as Adjunct Faculty at St. Jude Children's Research Hospital in Memphis, TN, USA. Her research focuses on understanding how ubiquitin and ubiquitin-like proteins regulate cellular processes through protein modification. Dr. Schulman's research interests center on structural biology of the ubiquitin-proteasome system and ubiquitin-like proteins. Her work has shown that hundreds of dynamic multiprotein complexes are transiently converted into different conformations by specialized regulatory factors that control ubiquitin and ubiquitin-like proteins, thereby monitoring virtually all processes in cell biology. She combines biochemical reconstitution, structural analysis, enzymology, protein design, cell biology, and genetics to understand how these molecular machines function. Her research has significant implications for understanding diseases such as cancer, neurodegenerative disorders, and viral infections where defects in ubiquitin pathways are implicated. Her extensive publication record demonstrates expertise in ubiquitin signaling, protein degradation mechanisms, structural biology of E3 ligases, and molecular machines. Her work spans from fundamental mechanisms of ubiquitin chain formation to therapeutic applications in targeted protein degradation. Among her numerous scientific accolades are the Feldberg Prize for Anglo-German Scientific Exchange (2025), ERC Advanced Grant (2023), Louis-Jeantet Prize for Medicine (2023), Gottfried Wilhelm Leibniz Prize (2019), and election to the National Academy of Sciences (2014). She has also received the Dorothy Crowfoot Hodgkin Award from The Protein Society and has been an Investigator of the Howard Hughes Medical Institute. Dr. Schulman leads an active research group that has produced numerous high-impact publications in top journals including Nature, Cell, and Nature Structural & Molecular Biology. Her team has made significant contributions to understanding the structural mechanisms of ubiquitin transfer, E3 ligase specificity, and the role of ubiquitin in cellular quality control pathways. Current research in her lab focuses on deciphering the ubiquitin code and developing novel approaches for targeted protein degradation.

• Structural biology
• Ubiquitin-proteasome system
• Ubiquitin-like proteins
• +5 more

Professor Stephan A. Sieber is a leading researcher in bioorganic chemistry at the Technical University of Munich (TUM), where he holds the Chair of Organic Chemistry II within the TUM School of Natural Sciences. His research program focuses on developing new drugs against multidrug-resistant bacteria through a multi-disciplinary approach that integrates synthetic chemistry, functional proteomics, microbiology, and protein biochemistry. His laboratory has made significant contributions to identifying unprecedented antibacterial targets beyond the scope of current antibiotics and exploiting these for chemical manipulation. Recent work has increasingly incorporated machine learning approaches to accelerate antibiotic discovery, with notable publications on AI-guided pipelines, drug-target interaction prediction, and high-throughput screening optimization. Sieber's research has resulted in the discovery of new active substances, some of which are currently being optimized for medical applications. His group's publications reveal a strong focus on chemical proteome mining, natural product mode of action studies, and novel antibacterial target identification. The lab has published extensively in top journals including Nature Chemistry, Nature Communications, and ACS Central Science. Inhoffen Medal (2024) Max Bergmann Medal (2023) ERC Advanced Grant (2023) Merck Future Insight Prize (2020) Klaus Grohe Prize (2020) ERC Consolidator Grant (2016) Professor Sieber leads an active research group that maintains a strong presence in the scientific community through regular publications, conference presentations, and collaborations. His laboratory website and BlueSky presence (@sieberlab.bsky.social) demonstrate ongoing research activities and engagement with the broader scientific community. He has successfully secured significant research funding including multiple ERC grants that have supported his innovative work in antibiotic discovery.

• Bioorganic Chemistry
• Antibiotic Development
• Chemical Proteomics
• +5 more

Prof. Dr. Karin Schumacher is a Professor of Plant Developmental Biology at Heidelberg University and currently serves as Vice-Rector for Quality Development and Sustainability. Her research focuses on plant cell biology, particularly vacuole dynamics, ion homeostasis, and membrane trafficking in Arabidopsis. She leads the Cell Biology Research Group at the Centre for Organismal Studies (COS) and has held leadership roles such as Dean of the Faculty of Biosciences. Her work integrates computational modeling with experimental approaches to study plant growth and stress responses. Dr. Schumacher's academic career includes a Doctorate from the University of Cologne and a Habilitation from the University of Tübingen. She has held professorial positions since 2007 and contributed to advancements in understanding plant membrane systems, including V-ATPase function and calcium signaling. Her research publications emphasize vacuolar ion transport, autophagy mechanisms, and plant stress physiology. Her administrative roles include enhancing early career researcher support and promoting sustainability in university operations. She is an active member of scientific societies like the German Botanical Society and serves on editorial boards such as Plant Cell . Her interdisciplinary work bridges cell biology, molecular genetics, and systems-level plant physiology.

• Cell Biology
• Plant Developmental Biology
• Plant Cell Biology
• +3 more

Matthias Feige is an Associate Professor of Cellular Protein Biochemistry at the Technical University of Munich (TUM). He leads the Focus Group for Cellular Protein Biochemistry, previously serving as a Rudolf Mößbauer Tenure Track Assistant Professor. His research focuses on understanding cellular proteome integrity, particularly in the secretory pathway, combining protein biochemistry and cell biology. Key interests include protein folding, quality control mechanisms, and their biomedical applications. Education & Career: PhD in Biochemistry (2009), TUM under Johannes Buchner Postdoctoral Fellowship at St. Jude Children’s Research Hospital (Memphis, USA) with Linda Hendershot Head of the Cellular Protein Biochemistry Lab at TUM since 2015 Research Interests: Feige’s work explores molecular mechanisms governing protein biogenesis, secretory pathway proteins, and their roles in immunity. His interdisciplinary approach targets fundamental biology and translational applications like protein engineering and therapy development. Scientific Contributions: His publications highlight advancements in cytokine assembly, ER quality control, and protein aggregation mechanisms. Notable recent work includes studies on KDELR3 signaling, helminth immune modulation, and engineered cytokines. Awards & Recognition: Leopoldina Fellowship (2011–2014) Fellow of the Daimler and Benz Foundation (2016) Rainer Rudolph Award (2012) Multiple honors from TUM and international institutions Labs & Teams: He directs a lab investigating protein biogenesis and proteostasis. Collaborations span biochemistry, immunology, and structural biology, with a focus on translational research.

• Protein Biochemistry
• Cell Biology
• Immunology
• +3 more

David R. Liu is the Thomas Dudley Cabot Professor of the Natural Sciences at Harvard University and the Richard Merkin Professor at the Broad Institute. He serves as a principal investigator at the Howard Hughes Medical Institute and director of the Merkin Institute of Transformative Technologies in Healthcare. His laboratory pioneers revolutionary genome editing technologies with profound implications for basic research and therapeutic development. Liu's research spans multiple disciplines at the intersection of chemistry and biology: Organic Chemistry Chemical Biology Biochemistry Genetic Engineering Genome Editing Technologies He pioneered base editing and prime editing techniques that enable precise DNA modifications without creating double-stranded breaks, overcoming key limitations of traditional CRISPR-Cas9 systems. His work on DNA-templated synthesis and phage-assisted continuous evolution (PACE) has transformed protein engineering and drug discovery approaches. Liu's contributions have been recognized with numerous prestigious awards: ACS Award in Pure Chemistry (2006) Election to National Academy of Medicine (2020) Election to National Academy of Sciences (2021) King Faisal Prize (2022) Breakthrough Prize in Life Sciences (2025) As an entrepreneur, Liu has co-founded multiple biotechnology companies including Editas Medicine, Beam Therapeutics, and Prime Medicine to translate his discoveries into therapeutic applications. His laboratory continues to advance genome editing technologies while developing novel approaches to treat genetic diseases through precise DNA modifications.

• Organic Chemistry
• Chemical Biology
• Biochemistry
• +7 more

PD Dr. Michael Veit is an Associate Professor (Privatdozent) at the Institute of Virology, School of Veterinary Medicine, Freie Universität Berlin , where he heads the independent Research Group Veit – Cell Biology of Viral Infections . He is a faculty member of the Center for Infection Medicine and participates in the Berlin Equine Virus Lab (BEVL). Education & Training Doctorate (Dr. rer. nat.) in Virology/Biochemistry – exact institution not stated in text. Post-doctoral qualification (Privatdozent) awarded by Freie Universität Berlin. Research Focus Veit’s laboratory investigates the molecular and cellular biology of enveloped RNA viruses , with emphasis on virus–host membrane interactions and post-translational lipid modifications (S-acylation/palmitoylation). His group combines reverse genetics, live-cell imaging, mass spectrometry and structural approaches to dissect how viral glycoproteins are modified, trafficked and assembled into infectious particles. Model pathogens include influenza A, B, C and D viruses, coronaviruses (SARS-CoV-2, MERS-like CoVs, PHEV, PDCoV), arteriviruses (PRRSV, EAV), alphaviruses (Getah, CHIKV-like), and other emerging zoonotic agents. Publication Trends From 2020 to 2025 Veit has published >30 high-impact articles that cluster around four major themes: (i) coronavirus surveillance and zoonotic risk assessment , (ii) mechanistic dissection of protein acylation in influenza and arteriviruses , (iii) structure-function analysis of viral entry receptors (ACE2, LDLR), and (iv) development of reverse-genetic tools and reporter viruses for antiviral screening. Grants & Collaborative Networks Ongoing third-party funded projects coordinated by Veit are not explicitly listed in the text, but the continuous publication output and mention of “Current Collaborations” imply active grant support. He collaborates closely with other FU Berlin groups (Osterrieder, Kaufer, Azab) and international partners on coronavirus and influenza consortia. Laboratory & Teams The Research Group Veit comprises post-docs, PhD students and technicians working in BSL-2 and BSL-3 facilities at the Institute of Virology. Core platforms include confocal & FLIM microscopy, quantitative proteomics, and reverse-genetics suites for segmented RNA viruses.

• Virology
• Viral Cell Biology
• Virus–Host Membrane Interactions
• +5 more

Dr. Shahaf Peleg is the Head of the Energy Metabolism and Epigenetics Working Group at the Research Institute for Farm Animal Biology (FBN). His research focuses on aging biology, epigenetic mechanisms, and metabolic interventions. Key areas include histone acetylation regulation, mitochondrial function, and dietary effects on longevity. He uses models like Drosophila, C. elegans, and mice (e.g., Titan mouse) to study aging pathways. Leading interdisciplinary projects on energy metabolism and epigenetic interactions. Developing optogenetic tools for mitochondrial research. Expertise in lipidomics and circadian metabolism. Recent work emphasizes dietary interventions in obesity-related aging and optogenetic rejuvenation of cellular energetics. Active in collaborative networks like ARDD Emerging Science workshops. Publications span metabolic pathway analysis, alcohol's epigenetic impacts, and longevity biomarkers. His team's Titan mouse model is a key tool for testing frailty attenuation strategies.

• Aging Biology
• Epigenetics
• Metabolic Regulation
• +7 more

Seraphine V. Wegner is a Full Professor at the Institute of Physiological Chemistry and Pathobiochemistry within the Medical Faculty of the University of Münster. She leads an active research group focused on the spatiotemporal control of cell-material and cell-cell interactions using visible light. Her work bridges synthetic biology, cell biology, and photochemistry to create innovative approaches for tissue engineering and minimal cellular systems. Dr. Wegner's educational background includes a PhD from the University of Chicago (2005-2010) and undergraduate studies at Middle East Technical University in Turkey (2002-2005). Her career path has taken her through prestigious institutions including the Max Planck Institutes in Mainz and Heidelberg, where she established her independent research before joining the University of Münster as a Full Professor in 2019. Her research spans several interconnected areas including light-controlled minimal cellular systems, photoswitchable cell-cell interactions for tissue engineering, light-controlled cell-material interactions, and engineering designer biofilms with light. These research themes share a common thread of using light as a non-invasive tool to precisely control biological processes with high spatial and temporal resolution. Dr. Wegner's publication record shows consistent high-impact output across leading journals in cell biology, synthetic biology, and materials science. Her recent work demonstrates increasing sophistication in multi-color light control systems and applications in both fundamental biological questions and potential therapeutic approaches. ERC Consolidator Grant (2024): LIGHTHOUSE - Light as a signal for nonchemical cell-to-cell communication ERC Starting Grant (2018): ARTIST - Artificial cell-cell interactions for light switchable cell organization and signaling Young Leaders in Science Program, Schering Foundation (2016) MaxSynBio Independent Group Leader, BMBF/MPG (2015) Her research group actively collaborates across disciplines, with projects spanning from fundamental biophysics of cell adhesion to potential medical applications in tissue engineering and bacterial therapeutics. Dr. Wegner has established herself as a leader in the emerging field of optogenetic control of multicellular systems.

• Synthetic Biology
• Cell Biology
• Photochemistry
• +5 more

Christian Freund is Professor of Protein Biochemistry at the Institute for Chemistry & Biochemistry, Freie Universität Berlin, holding this W2 professorship since 2011. He serves as Coordinator of the FU Berlin-UCSF Collaborative Initiative and Founding Member/Vice-chair of the DFG Collaborative Research Centre SFB/TRR 186 on Molecular Switches in Cellular Signal Transmission, leading interdisciplinary research across Berlin and Heidelberg institutions. His academic foundation includes Chemistry studies at Heinrich-Heine-Universität Düsseldorf (1983-1986) and Ludwig-Maximilians-Universität München (1986-1989), followed by a PhD in Structural Biology at the Max-Planck-Institute of Biochemistry (1994) and Habilitation in Biochemistry at Freie Universität Berlin (2005). Freund's research integrates structural biology, biophysics, and immunology to investigate molecular mechanisms of antigen presentation and cellular signaling. His work centers on MHC class II dynamics, protein conformational switches, and nanoscale organization of signaling complexes, employing NMR spectroscopy, quantitative proteomics, and molecular engineering to dissect immune recognition pathways and neuronal signaling mechanisms. Analysis of his 2010-2019 publications reveals consistent focus on MHC-mediated antigen presentation (60% of works), with significant contributions to understanding peptide exchange dynamics and HLA-DM editing functions. Secondary research streams explore synaptic protein networks (25%) and T cell signaling machinery (15%), demonstrating methodological breadth across structural biology, proteomics, and cell biological approaches. His scientific recognition includes: Biofuture award from the German Ministry of Education and Research (1999) Swiss National Funds Post-doctoral Scholarship (1997) Innovationswettbewerb Medizintechnik grant (2009) As research group leader at Leibniz-Institute of Molecular Pharmacology (2000-2011) and current FU Berlin professor, Freund has secured major collaborative funding through DFG SFB/TRR 186 and the UCSF partnership. His mentorship spans postdoctoral fellows at Harvard/Dana-Farber and Leibniz-Institute, with current supervision of graduate students in the Berlin biochemistry program. Freund directs a research group within FU Berlin's Institute for Chemistry & Biochemistry, operating as core component of SFB/TRR 186. His laboratory maintains active collaborations with UCSF's QBI (Nevan Krogan) and Heidelberg-based structural biology teams, utilizing advanced NMR, cryo-EM, and single-molecule imaging facilities across the Berlin-Heidelberg research alliance.

• Protein Biochemistry
• Immunology
• Structural Biology
• +3 more

Prof. Dr. Bettina Siebers is a full Professor at the University of Duisburg-Essen, Faculty of Chemistry, where she leads the research group Molecular Enzyme Technology and Biochemistry (MEB). Her work is embedded in the Zentrum für Medizinische Biotechnologie (ZMB) and focuses on hyperthermophilic archaea, central carbohydrate metabolism, and biotechnological applications of extremozymes. She is actively involved in funded research projects, including a major €1.4 million grant from the VolkswagenStiftung for sustainable bio-production. Research Interests: Her research spans archaeal biochemistry, systems biology, metabolic engineering, and enzyme technology. She investigates the unique metabolic pathways in archaea, particularly under extreme conditions, combining classical biochemistry with genomics, transcriptomics, and computational modelling. Her group explores transcription regulation, stress responses, and protein phosphorylation in archaea as simplified models for eukaryotic processes. Publication Trends: Her recent publications emphasize enzyme cascade optimization, extremozyme discovery, metabolic pathway modelling (e.g., Weimberg pathway), and archaeal gene regulation. The interdisciplinary work bridges microbiology, biotechnology, and systems biology, with strong applications in sustainable bioproduction and industrial biocatalysis. Scientific Recognition: Lead Principal Investigator, VolkswagenStiftung 'Biofabrik' Project (€1.4 million) Active publications in high-impact journals including Nature , Nature Communications , FEMS Microbiology Reviews , and Nucleic Acids Research Member of ZMB and contributor to DFG, EU, and NRW-funded research programs Advising and Grants: While specific students are not listed, her group includes postdocs and researchers such as Dr. Christopher Bräsen. She leads major funded projects, including the VolkswagenStiftung initiative to replace microplastics with microbial lipids. Her work is supported by national and international collaborations, particularly with TU Wien. She integrates fundamental research with translational biotechnological applications. Labs and Teams: The MEB group at the University of Duisburg-Essen comprises a dedicated team including a laboratory manager, secretariat, and researchers. The group is part of the ZMB and collaborates within the Faculty of Chemistry and beyond, focusing on extremophile biochemistry and sustainable biotechnology.

• Archaea
• Central Carbohydrate Metabolism
• Extremozymes
• +13 more

Professor Johanita Kruger is a faculty member at the University of Applied Sciences Fulda, Germany, where she holds the position of Professor of Food Technology and Nutrition. Previously, she has held roles including Researcher at the University of Hohenheim and Lecturer at the University of Pretoria. Her research focuses on nutrient bioavailability, particularly inhibitors and enhancers of bioactive compounds, with an emphasis on polysorbate micelle absorption mechanisms, food-to-food fortification strategies, and mineral bioavailability in African green leafy vegetables. She collaborates internationally on projects funded by the German Research Foundation (DFG) and USAID, addressing issues such as micronutrient deficiencies and food processing innovations. Her educational background includes a PhD in Nutrition from the University of Pretoria, alongside extensive post-doctoral and research experience across multiple institutions. University of Applied Sciences Fulda, Germany (2023–present) University of Hohenheim, Stuttgart (2020–2023; 2016–2018) University of Pretoria, South Africa (2015–2015; 2011–2013) Her research interests span food biofunctionality, including the development of novel micellar formulations and the evaluation of food processing techniques to enhance nutrient bioavailability. Key projects include defining food-to-food fortification strategies and investigating iron/zinc bioavailability in traditional African diets. She has contributed to interdisciplinary collaborations, such as the USAID Feed the Future Innovation Lab for Food Processing. Publications highlight advancements in polysorbate micelle stability, polyphenol encapsulation, and the efficacy of tropical plant-based fortification. Her work bridges laboratory research and real-world applications, aiming to improve global food security and nutritional outcomes. Laboratory activities include the USAID-funded Food Processing Lab and collaborative projects with institutions in France and Slovenia. No scientific awards are explicitly noted in the provided text. Her advising and grants include DFG funding for micelle absorption studies and contributions to the Kenyan Flour Blending Initiative. Students and lab teams focus on topics like cereal biofortification and nutrient-micelle interactions.

• Food Science
• Nutritional Bioavailability
• Food Fortification Strategies
• +3 more

Dr. Aydan Bulut-Karslıoğlu is a Research Group Leader at the Max Planck Institute for Molecular Genetics in Berlin, where she leads the Bulut-Karslıoğlu Lab focused on gene-environment interactions in stem cells and development. Her work has significantly advanced our understanding of embryonic diapause and stem cell state transitions. Dr. Bulut-Karslıoğlu's educational background includes: B.Sc. in Chemical Engineering (major) and Biology (minor) from Middle East Technical University, Ankara, Turkey (2006) M.Sc. in Molecular Biology and Genetics from Bilkent University, Ankara, Turkey (2008) Ph.D. from Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany (2013) Her research focuses on mechanisms regulating stem cell state transitions and fate commitment, particularly how cells communicate signals from their surroundings to the gene expression machinery. She has pioneered work on mammalian embryonic diapause - a reversible dormant state that gives embryos extra time to develop. Her lab uses a combination of functional perturbation methods in stem cells and early mouse embryos with omics, imaging, and biochemistry to reveal how genetic networks adjust to the status of the embryo. Analysis of her recent publications reveals a strong focus on the epigenetic and metabolic regulation of embryonic diapause, with particular emphasis on mTOR signaling, lipid metabolism, and DNA methylation dynamics. Her work bridges developmental biology, stem cell research, and metabolism, demonstrating how environmental cues like oxygen levels and nutrient availability influence developmental timing and cell fate decisions. Her notable scientific achievements include: Sofja Kovalevskaja Award (2018) ERC Starting Grant (2023) ERC Proof of Concept Grant (2025) GSCN Young Investigator Award (2025) Dr. Bulut-Karslıoğlu actively mentors the next generation of scientists, currently supervising multiple PhD students including Persia Akbari-Omgba, Anastasios Balaskas, Heleen Mallie, and Gunwant Patil. Her lab has received substantial funding through prestigious grants, including the Sofja Kovalevskaja Award, ERC Starting Grant, and ERC Proof of Concept Grant, enabling her team to pursue innovative research at the intersection of developmental biology and metabolism. The Bulut-Karslıoğlu Lab maintains a vibrant research environment with both computational and experimental scientists working together to unravel the mysteries of embryonic diapause and stem cell regulation. The lab actively participates in the International Max Planck Research School for Biology And Computation (IMPRS-BAC), contributing to the training of doctoral candidates at the interface of molecular life sciences and computational sciences.

• Embryonic diapause
• Stem cell state transitions
• Fate commitment
• +7 more